We’re excited to share our latest work focused on evaluating synthetic cytokines to enhance the production and performance of promising off-the-shelf cell therapies for treating cancer. We engineered natural killer-like NK92 cells to express six synthetic cytokines and evaluated their utility for driving expansion, cancer cell killing, and resistance to tumor microenvironmental conditions. Congratulations to Simrita, Patrick, Roxi, and Iva. Check out the paper here!
